What are the guidelines for treating postpartum depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Treatment for postpartum depression should involve a combination of psychotherapy, medication, and support systems, with telemental health interventions being a viable option, as they have been shown to be efficacious in reducing postpartum depression symptoms compared to usual care 1.

Key Components of Treatment

  • First-line medication options include selective serotonin reuptake inhibitors (SSRIs) such as sertraline, fluoxetine, or escitalopram, which should be continued for at least 6-12 months after symptom resolution to prevent relapse.
  • Cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) is highly effective, either alone or combined with medication, and can be delivered through telemental health interventions.
  • Practical support measures, such as ensuring adequate sleep, accepting help with childcare and household tasks, joining support groups, and maintaining social connections, are also crucial.

Screening and Assessment

  • The Edinburgh Postnatal Depression Scale (EPDS) is currently the best available patient-reported outcome measure (PROM) for screening for maternal postpartum depression, although clinicians should be aware of its strengths and weaknesses 1.
  • Early diagnosis and treatment of postpartum depression are essential to minimize disease severity and associated morbidity.

Special Considerations

  • Breastfeeding mothers can generally take SSRIs, with sertraline and paroxetine having minimal transfer to breast milk.
  • For severe cases with suicidal ideation or psychosis, immediate psychiatric evaluation is necessary, and hospitalization may be required.

Future Directions

  • Further research is needed to evaluate the cross-cultural validity, reliability, and measurement error of the EPDS and to assess the psychometric properties of other PROMs 1.
  • Integrative studies that combine biological and psychosocial factors are necessary to advance our knowledge of postpartum depression etiology 1.

From the Research

Guidelines for Treating Postpartum Depression

  • The treatment of postpartum depression can include pharmacological and psychological interventions 2.
  • Selective serotonin reuptake inhibitors (SSRIs), such as sertraline, are generally considered the first-line antidepressant medication for postpartum depression due to their minimal passage into breastmilk and safety data 2, 3, 4.
  • Sertraline has been shown to be effective in treating postpartum depression, with a significantly greater response rate and remission rate compared to placebo 3.
  • Psychological treatments, such as cognitive-behavioral therapy, are also effective and preferred by many perinatal patients, but may be inaccessible due to barriers such as lack of specialist providers and stigma 2, 5.
  • Neurosteroids are emerging as a potential treatment for postpartum depression, although this treatment is not yet widely available 2.
  • Other treatment options, such as hormonal therapy with oxytocin and brexanolone, are also being studied and have shown promise in treating postpartum depression 6.
  • Non-pharmacological therapies, such as bright light therapy and vagal nerve stimulation, may also be effective for breastfeeding mothers who are reluctant to use pharmacotherapy 6.

Treatment Considerations

  • When selecting a treatment for postpartum depression, it is essential to consider the individual patient's needs and circumstances, including their breastfeeding status and any potential contraindications to medication 4.
  • Providers should be prepared to diagnose depression, prescribe first-line antidepressants, and refer patients to other professionals as needed 4.
  • Barriers to treatment, such as lack of access to specialist providers and stigma, should be addressed to ensure that patients receive the care they need 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

An update on the pharmacotherapy of postpartum depression.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.